A Clinical Study to Evaluate the Efficacy and Safety of the Injection With UNIVELO Sub-Q, as Compared to Restylane® Sub-Q, in the Temporary Correction of the Nasolabial Fold

Inclusion Criteria: * Subjects who desire temporary improvement of both nasolabial folds and who has rated 3 or 4 on the Wrinkle Severity Rating Scale (WSRS) (the rating does not have to be the same for both sides) * Subjects who have agreed to discontinue all dermatological treatments or procedures, including those for facial wrinkles improvement in the facial area, during the clinical trial period * Subjects capable of understanding and complying with directions and who can participation for the full duration of the clinical trial period * Subjects who have voluntarily decided to participate in the clinical trial and have given written consent by signing the subject informed consent form Exclusion Criteria: * Subjects who have been administered an antithrombotic agent (with the exception of low dosage aspirin (100mg, maximum 300mg/day)) within 2 weeks of the date of the screening * Subjects who have had a history of any bleeding disorder, in the past or the present